Investigate how host, pathogen, and environmental factors interact to influence infection, disease progression, and resistance, ultimately supporting the development of evidence-based interventions. such as vaccines, new therapeutics, and infection-blocking strategies.
It will strengthen collaboration among the research groups by integrating molecular, clinical, and population-level approaches to infectious disease research.
HPI will bridge laboratory-based discoveries with clinical and public health applications, ensuring that mechanistic insights from PRIME and VBD are translated into transmission control tools, patient care and health policy through CTM and PPS, in alignment with GHTM’s OH and GH missions.
HPI will establish shared data and sample pipelines linking laboratory, vector, and clinical cohorts, supported by infrastructures such as VIASEF, BIOTROP, and the Bioinformatics Hub.
Projects will address host-associated protection mechanisms, immunopathogenesis and disease severity,microbial virulence and drug resistance mechanisms, vector competence, microbiome interactions, and environmental determinants of transmission. Cutting-edge methodology, molecular and cellular biology, omics, spatial modeling, and AI-assisted analysis will be employed to generate joint outputs such as biomarker discovery, molecular signatures for early diagnosis, and candidate molecules for transmission blocking or drug development.
Findings will integrate into CTM-led clinical protocols and PPS-led implementation studies, promoting feasible and equitable disease control solutions, particularly in PALOP and other endemic regions. Joint training programs and advanced methodological workshops will foster capacity building and sustained interdisciplinary collaboration (eg. MulhereSTrop).
Recent Highlights
GHTM Sessions | Schistosomiasis in China: Practical Experiences in Infection Control and Eradication Efforts
Join us on 7 September at 15h30 (Lisbon time) for Prof. Xiao-Nong Zhou’s GHTM session on schistosomiasis in China, exploring practical experiences in infection control, surveillance and eradication efforts.
Read More
GHTM researcher Ana Armada appointed to the Management Committee of COST Action – ONE-LEP
Ana Armada joins the ONE-LEP Management Committee, strengthening Portugal’s role in One Health research on leptospirosis and rodent-borne diseases.
Read More
Facilitator
